Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging
Open accessThe DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.
Abstract
Synapses are implicated in many neuropsychiatric illnesses. Here, we provide an overview of in vivo techniques to index synaptic markers in patients. Several positron emission tomography (PET) tracers for synaptic vesicle glycoprotein 2 A (SV2A) show good reliability and selectivity. We review over 50 clinical studies including over 1700 participants, and compare findings in healthy ageing and across disorders, including addiction, schizophrenia, depression, posttraumatic stress disorder, and neurodegenerative disorders, including tauopathies, Huntington’s disease and α-synucleinopathies. These show lower SV2A measures in cortical brain regions across most of these disorders relative to healthy volunteers, with the most well-replicated findings in tauopathies, whilst changes in Huntington’s chorea, Parkinson’s disease, corticobasal degeneration and progressive supranuclear palsy are predominantly subcortical. SV2A PET measures are correlated with functional connectivity across brain networks, and a number of other measures of brain function, including glucose metabolism. However, the majority of studies found no relationship between grey matter volume measured with magnetic resonance imaging and SV2A PET measures. Cognitive dysfunction, in domains including working memory and executive function, show replicated inverse relationships with SV2A measures across diagnoses, and initial findings also suggest transdiagnostic relationships with mood and anxiety symptoms. This suggests that synaptic abnormalities could be a common pathophysiological substrate underlying cognitive and, potentially, affective symptoms. We consider limitations of evidence and future directions; highlighting the need to develop postsynaptic imaging markers and for longitudinal studies to test causal mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Colocalisation of SV2A and synaptophysin in the baboon brain. a High-power confocal microscopy of 4’,6-diamidino-2-phenylindole (DAPI), synaptophysin (SYN), and synaptic vesicle glycoprotein 2A (SV2A) in the grey matter of the baboon brain. Labelling for SYN and SV2A is evident as punctate staining in the neuropil, particularly surrounding neuronal cell bodies and proximal dendrites (yellow arrow), but absent in neuronal cell bodies (white arrows). Nuclei are indicated by the DAPI stain in blue. b Correlation between in vitro SV2A and in vitro SYN density in grey matter regions determined using Western blot analyses. Data are nine brain regions. Figure and legend reproduced from Finnema et al. with permission (2016) [47]. GM grey matter, OD optical density.](https://figures.cochat.ai/paper-figures/2c2f620148394437ad243a03bed4455e/synaptic-changes-in-psychiatric-and-neurological-disorders-state-of-the-art-of-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Depression cohorts show lower binding with evidence that pharmacologic challenges can probe synaptogenesis in vivo [212].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [212]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across disorders, SV2A PET consistently reveals synaptic loss [210,211,212].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [212]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NODDI: Practical in vivo neurite orientation dispersion and density imaging of the human brain
Zhang, H., Schneider, T., Wheeler-Kingshott, C. A., & Alexander, D. C. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.03.072 · Cited by 3,288
The Neural Basis of Addiction: A Pathology of Motivation and Choice
Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757
Synaptic Plasticity: Multiple Forms, Functions, and Mechanisms
Citri, A., & Malenka, R. C. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301559 · Cited by 2,323 · cited 1×
“The binding of neurotransmitter can produce diverse effects, including excitation, inhibition and induction of synaptic plasticity [12].”
BackgroundSynapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Synaptic Energy Use and Supply
Harris, J. J., Jolivet, R., & Attwell, D. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.019 · Cited by 1,747
Chemical Nature of Synaptic Transmission in Vertebrates
Krnjević, K. (1974) · Physiological Reviews · doi:10.1152/physrev.1974.54.2.418 · Cited by 1,610
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 2×
“One of the fi rst produced was [ 11 C]LEV, based on the SV2A modulator levetiracetam [22].”
BackgroundSynaptotagmin: a Calcium Sensor on the Synaptic Vesicle Surface
Brose, N., Petrenko, A. G., Südhof, T. C., & Jahn, R. (1992) · Science · doi:10.1126/science.1589771 · Cited by 979
Research works printed but not linked: 4
- Cai H, Mangner T, Muzik O, Chugani H. Radiosynthesis and preliminary evaluation of 11C-levetiracetam for PET imaging of SV2A expression. Soc Nuclear Med. 2014; 55:1795.
- Cai Z, Drake L, Naganawa M, Najafzadeh S, Pracitto R, Lindemann M. et al. First-in-human study of [18F] SynVesT-2, a novel SV2A radioligand with fast kinetics and high specific binding signals. Soc Nuclear Med. 2020;61:462 · DOI · Paper page
- Onwordi EC, Whitehurst T, Shatalina E, Mansur A, Arumuham A, Osugo M, et al. Synaptic Terminal Density Early in the Course of Schizophrenia: an in vivo UCB-J Positron Emission Tomographic Imaging Study of Synaptic Vesicle Glycoprotein 2A (SV2A). Biol Psychiatry 2023;S0006-3223:01353–7.
- Reichert JS. SV2A-just a synaptic vesicle protein? Unravelling the interaction of SV2A and mitochondria in the pathogenesis and therapy of Morbus Alzheimer. Dissertation, Mainz, Johannes Gutenberg-Universität Mainz, 2022;2022.
Cited by
Genetic Analysis of Retinal Cell Types in Neuropsychiatric Disorders
Boudriot, E., Stephan, M., Rabe, F., Smigielski, L., Schmitt, A., Falkai, P., Ziller, M. J., Rossner, M. J., Homan, P., Papiol, S., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4230 · Cited by 22
Bhujbal, S. P., & Hah, J. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01566-w · Cited by 18
Copper-mediated radiochemistry: historical impact, current trends, and future possibilities
Bowden, G. D., Müller, M., Herth, M. M., Sanford, M. S., & Scott, P. J. H. (2025) · npj Imaging · doi:10.1038/s44303-025-00087-x · Cited by 18
Vano, L. J., McCutcheon, R. A., Sedlacik, J., Rutigliano, G., Kaar, S. J., Finelli, V., Lobo, M. C., Berry, A., Statton, B. K., Fazlollahi, A., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03195-7 · Cited by 17
Self-citationGupta, R., Jha, N. K., Kumar, N., Nagraik, R., & Ravi, K. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1762930 · Cited by 16
Metadata
- Authors
- Howes, O., Marcinkowska, J., Turkheimer, F. E., & Carr, R.
- Affiliations
- King's College London (GB)
- Corresponding author
- Howes, Oliver
- Venue
- Neuropsychopharmacology
- Published
- 2024-08-12
- Volume
- 50
- Issue
- 1
- Pages
- 164-183
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC11525650
- OpenAlex
- W4401527108
- Cited by
- 34
- References
- 161
- Citations by year
- 2026: 19 · 2025: 14 · 2024: 1
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-03-19)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, cc-by)
- Funders
- RCUK | Medical Research Council (MC_U120097115, MR/W005557/1, MR/V013734/1)
- Wellcome Trust (094849/Z/10/Z)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- synaptic markers, SV2A, mental illness, neurological disorders, tauopathy, Huntington's disease, synucleinopathies, Parkinson's disease, corticobasal degeneration, progressive supranuclear palsy, schizophrenia, depression, post-traumatic stress disorder, addiction, functional connectivity, glucose metabolism, cognitive impairment, transdiagnostic mechanisms, healthy aging
- MeSH terms
- Animals, Mental Disorders, Brain, Humans, Nervous System Diseases, Synapses, Positron-Emission Tomography, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging. https://app.cochat.ai/papers/10.1038/s41386-024-01943-x
- The paper
- Howes, O., Marcinkowska, J., Turkheimer, F. E., & Carr, R. (2025). Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging. Neuropsychopharmacology. https://doi.org/10.1038/s41386-024-01943-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.